Oncolytics biotech incorporated ONCY.US Overview Analysis
ONCY AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
ONCY Current Performance
-8.00%
Oncolytics biotech incorporated
0.95%
Avg of Sector
0.77%
S&P500
Top 10 High Relevance to ONCY
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
AVBP | Arrivent biopharma inc | - | 4 | 3 | 1 | 1 | |
MURA | Mural oncology plc | - | 3 | 3 | 1 | 1 | |
EXAS | Exact sciences corporation | 3 | 5 | 5 | 3 | 1 | |
TGTX | Tg therapeutics inc | 3 | 3 | 4 | 3 | 1 | |
SGMT | Sagimet biosciences inc | - | 5 | 3 | 1 | 1 |
- AVBP Arrivent biopharma incValue -Trend 4Swing Trading 3Whale Interest 1Dividend 1See more
ONCY Profile
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company's primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.